Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008

Yakugaku Zasshi

Volumn 130, Issue 2, 2010, Pages 263-270

  Uchiyama, Nahoko ^a   Miyazawa, Norimasa ^b   Kawamura, Maiko ^a   Kikura Hanajiri, Ruri ^a   Goda, Yukihiro ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b SAITAMA INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

Designer drug; Drug abuse; GC MS; LC MS; NMR; Psychotropic substance

Indexed keywords

1 (2 FLUOROPHENYL) N METHYLPROPAN 2 AMINE; 1 (2,5 DIMETHOXY 4 ISOPROPYLSULFANYLPHENYL)PROPAN 2 AMINE; 1 (2,5 DIMETHOXY 4 NITROPHENYL)PROPAN 2 AMINE; DESIGNER DRUG; ETHYL 5 METHOXY N PROPYLTRYPTAMINE; PHENETHYLAMINE DERIVATIVE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABUSE; DRUG MARKETING; JAPAN; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE;

CHROMATOGRAPHY, LIQUID; DESIGNER DRUGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PHENETHYLAMINES; PSYCHOTROPIC DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TIME FACTORS;

EID: 76349121087     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.130.263     Document Type: Article

References (18)

1. 〈http://www.mhlw.go.jp/shingi/2006/11/ s1109-4.html〉, cited 15 July, 2009.
2. Kikura-Hanajiri R., Kawamura M., Uchiyama N., Ogata J., Kamakura H., Saisho K., Goda Y., Yakugaku Zasshi, 128, 971-979 (2008).
3. Uchiyama N., Kawamura M., Kamakura H., Kikura-Hanajiri R., Goda Y., Yakugaku Zasshi, 128, 981-987 (2008).
4. 〈http://www.mhlw.go.jp/shingi/2007/09/ s0920-4.html〉, cited 15 July, 2009.
5. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Goda Y., Yakugaku Zasshi, 128, 1499-1505 (2008).
6. Acuña-Castillo C., Villalobos C., Moya P.R., Sáez P., Cassels B. K., Huidobro-Toro J. P., Br. J. Pharmacol., 136, 510-519 (2002).
7. Rösner P., Quednow B., Girreser U., Junge T., Forensic Sci. Int., 148, 143-156 (2005).
8. Nonaka R., Nagai F., Ogata A., Satoh K., Biol. Pharm. Bull., 30, 2328-2333 (2007).
9. Marona-Lewicka D., Rhee G. S., Sprague J. E., Nichols D. E., Eur. J. Pharmacol., 287, 105-113 (1995).
10. Wee S., Anderson K. G., Baumann M. H., RothmanR. B., Blough B. E., Woolverton W. L., J. Pharmacol. Exp. Ther., 313, 848-854 (2005).
11. Negus S. S., Mello N. K., Blough B. E., Baumann M. H., Rothman R. B., J. Pharmacol. Exp. Ther., 320, 627-636 (2007).
12. Nagai F., Nonaka R., Satoh K., Kamimura H., Eur. J. Pharmacol., 559, 132-137 (2007).
13. Uchiyama N., Kikura-Hanajiri R., Goda Y., Wada M., Urade Y., Abstracts of papers, the 26th Congress of the Collegium Internationale Neuro- Psychopharmacologicum (CINP), Munich, July 2008, p. 235.
14. Clare B. W., J. Med. Chem., 33, 687-702 (1990).
15. Altun A., Golcuk K., Kumru M., Jalbout A. F., Bioorg. Med. Chem., 11, 3861-3868 (2003).
16. Thakur M., Thakur A., Khadikar P. V., Bioorg. Med. Chem., 12, 825-831 (2004).
17. Glennon R. A., Young R., Benington F., Morin R. D., J. Med. Chem., 25, 1163-1168 (1982).
18. Glennon R. A., Titeler M., McKenney J. D., Life Sci. 35, 2505-2511 (1984).